| DB ID | MyCo_1703 |
| Title | Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis |
| Year | 2018 |
| PMID | 29964232 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study protocol was approved by the Institute Ethics Committee of Jinling Hospital (2015NJKY-035-03), and written informed consent was obtained from all of the subjects. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Pentraxin 3 |
| Biomarker Full Name | Pentraxin 3 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | This was a prospective study conducted between March 2015 and November 2017 at the Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, China. 211 BALF samples and 307 plasma samples of patients with pulmonary aspergillosis were collected and divided into aspergillosis groups (BALF n = 51, 35 proven, 16 probable; plasma n = 89, 51 proven, 38 probable). Aspergillosis subjects were then divided into IPA, SAIA and CPA (excluding SAIA) subgroups (BALF: 17 IPA, 19 SAIA and 15 CPA; plasma: 28 IPA, 20 SAIA and 41 CPA). |
| Cohort No. | 431 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.863 |
| Specificity | 0.825 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pulmonary aspergillosis is a severe mycosis caused mainly by Aspergillus fumigatus. In recent years, reports of pulmonary aspergillosis have increased in non-neutropenic patients, including subjects with chronic obstructive pulmonary disease (COPD), cavitary pulmonary tuberculosis, bronchiectasis, chronic kidney disease, diabetes, patients who use glucocorticoids or immuno- suppressants, and for those with other critical conditions. Non-neutropenic patients with aspergillosis have atypical symptoms and imaging ndings, and early diagnosis is dif cult, contributing to a high mortality rate and unnecessary medical ex- penses. The updated Infectious Diseases Society of America (IDSA) guidelines recommend bronchoalveolar lavage uid (BALF) gal- actomannan (GM) and aspergillus IgG antibody testing for diag- nosing chronic forms of pulmonary aspergillosis. Our previous work has con rmed that the BALF galactomannan (GM) testing offers diagnostic value. However, invasiveness, numerous false positives, and the lack of standardization suggest that better bio- markers for diagnosing aspergillosis are needed, especially for the early diagnosis of invasive pulmonary aspergillosis (IPA) and sub- acute invasive aspergillosis (SAIA) in non-neutropenic patients. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (DPTX30, Quantikine Human Pentraxin 3 Immunoassay, R&D, USA). |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
